Drug Discovery World

APRIL 3, 2024

Join DDW for this free event, ‘ CRISPR screening at scale: Achieving 1M cell data sets with an instrument-free, cost-effective approach ‘ , which is supported by Scale Biosciences. The event will take place on 25 April 5 PM BST / 6PM CEST / 9AM PST. It will be presented by Dylan Mooijman, Head of R&D, Single Cell Discoveries and Darina Šikrová, Researcher, Molecular Biology, Single Cell Discoveries.

Molecular Biology 130

Molecular Biology RNA Drugs Research 130

Chemical Biology and Drug Design

APRIL 3, 2024

The present review explores the intricate relationship between autophagy and proteostasis in the pathogenesis of neurodegenerative diseases along with the therapeutic interventions to mitigate the same. Abstract Neurodegenerative disorders are devastating disorders characterized by gradual loss of neurons and cognition or mobility impairment. The common pathological features of these diseases are associated with the accumulation of misfolded or aggregation of proteins.

Disease 100

Disease Treatment Research 100

Drug Discovery World

APRIL 3, 2024

A public-private consortium formed by the biotech Hemostatics, based at the Barcelona Science Park, the Clínica Universidad de Navarra (CUN) and the Institute of Chemical Research of Catalonia (ICIQ), has received €2.5 million from the Spanish Research Agency (AEI), under the call for grants for Public-Private Collaboration Projects, to accelerate the development of an innovative treatment aimed at controlling disabling and lethal haemorrhage.

Therapies 130

Therapies Laboratories Pharmacokinetics Treatment 130

Science Daily: Pharmacology News

APRIL 3, 2024

A fungus devastating frogs and toads on nearly every continent may have an Achilles heel. Scientists have discovered a virus that infects the fungus, and that could be engineered to save the amphibians.

Engineering 122

Engineering Virus 122

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drug Discovery World

APRIL 3, 2024

While the age-adjusted overall cancer death rate in the US fell by 33% between 1991 and 2020, cancer remains a significant threat to human health, with more than two million new cases expected to be diagnosed in 2024 and uneven progress across different cancer types 1. These figures demonstrate that the development of highly effective targeted therapeutics and immunotherapies is more important than ever, despite the astonishing rate of progress.

Targeted Protein Degradation 130

Targeted Protein Degradation Research Therapies Drugs 130

BioPharma Drive: Drug Pricing

APRIL 3, 2024

The startup claims to have a more efficient way to develop biologic drugs that treat disease by turning on cellular pathways, rather than blocking them.

Drugs 117

Drugs Disease 117

Science Daily: Pharmacology News

APRIL 3, 2024

A new study is among the first of its kind to separate activity relating to emotion generation from emotion regulation in the human brain. The findings provide new insights that could help inform therapeutic treatments regarding mental health and drug addiction.

Regulations 105

Regulations Research Treatment Drugs 105

Conversations in Drug Development Trends

APRIL 3, 2024

By: Sue Batchelor, Executive Director, Oncology Project Management Radiopharmaceuticals represent a cutting-edge frontier in oncology treatment, offering the promise of highly targeted therapy with the potential to revolutionize cancer care. As with other targeted therapies, radiopharmaceutical development requires unique and specialized strategies to ensure successful execution.

Trials 81

Trials Clinical Trials Compliance Treatment 81

Science Daily: Pharmacology News

APRIL 3, 2024

Researchers have developed a programmable meta-fluid with tunable springiness, optical properties, viscosity and even the ability to transition between a Newtonian and non-Newtonian fluid. The first-of-its-kind meta-fluid uses a suspension of small, elastomer spheres -- between 50 to 500 microns -- that buckle under pressure, radically changing the characteristics of the fluid.

Research 91

Research 91

BioPharma Drive: Drug Pricing

APRIL 3, 2024

The buyout continues a surge in M&A for developers of antibody-drug conjugates and gives Genmab a potential competitor to a medicine AbbVie recently purchased in a multibillion-dollar acquisition.

Drugs 73

Drugs 73

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Science Daily: Pharmacology News

APRIL 3, 2024

A team of astronomers has used NASA's James Webb Space Telescope to survey the starburst galaxy Messier 82 (M82). Located 12 million light-years away in the constellation Ursa Major, this galaxy is relatively compact in size but hosts a frenzy of star formation activity. For comparison, M82 is sprouting new stars 10 times faster than the Milky Way galaxy.

81

81

BioPharma Drive: Drug Pricing

APRIL 3, 2024

Oruka Therapeutics is the third startup from Paragon to go public since last year, and the second to do so by combining with another biotech.

70

70

Science Daily: Pharmacology News

APRIL 3, 2024

New research makes a case study of Yellowstone National Park -- calculating surplus carbon that visitors from across the world add to the atmosphere each year as a direct result of a park visit.

Research 74

Research 74

Cytel

APRIL 3, 2024

Thank you to Charlotta Gauffin, Chief Scientific Officer at Dicot, for joining us for our recent webinar, “The Road to First-in-Human Trials: Insights from a Real-World Example.” Thoughtfully and carefully planned nonclinical studies help pave a smooth path toward first-in-human Phase 1 clinical trials. This involves a collaboration between all areas of nonclinical development, including CMC, toxicology, pharmacology, DPMK, and so on, and keeping in mind early a plan that all stakeholders agree

Clinical Trials 59

Clinical Trials Drugs Trials Drug Development 59

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Science Daily: Pharmacology News

APRIL 3, 2024

Researchers have genetically engineered bacteria to grow animal- and plastic-free leather that dyes itself.

Engineering 88

Engineering Research 88

NIOSH Science Blog: Drugs

APRIL 3, 2024

March was Women’s History Month and this year’s theme was “Women Who Advocate for Equity, Diversity and Inclusion.” This theme urged us to think about the diversity of U.S. women workers and how NIOSH is addressing health equity. Health equity is the state in which everyone has a fair and just opportunity to attain their highest level of health.[1] Occupational health inequities [2] can be influenced by exclusion and discrimination based on factors such as gender, socioeconomic position, and rac

Research 60

Research 60

Science Daily: Pharmacology News

APRIL 3, 2024

A new study finds that UCYN-A, a species of nitrogen-fixing cyanobacteria, may be evolving organelle-like characteristics.

81

81

Fierce BioTech

APRIL 3, 2024

Mini-Organs, Major Breakthroughs: How Hub Organoids Are Accelerating Oncology Drug Development dwunderlin Wed, 04/03/2024 - 17:28 Tue, 05/14/2024 - 09:30 Resource Type Webinar Dr. Sylvia F. Boj Duration 60 Minutes Patient-derived organoids are viewed as the gold standard in bridging the gap between the lab and the clinic. Advancements in HUB Organoid Technology, using patient material to generate “mini-organs” in a dish, have revolutionized in vitro predictivity over conventional 2D cell culture

Drug Development 52

Drug Development Drugs Therapies Treatment 52

Science Daily: Pharmacology News

APRIL 3, 2024

Researchers gave nanorobots a trait called adaptive time delay, which allows them to better work together.

Research 85

Research 85

Drug Channels

APRIL 3, 2024

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. The 2024 formularies described below should boost biosimilar adoption. As a new Biosimilar Council report shows , Humira retained 99% of market share in late 2023, despite being more expensive than its biosimilars.

Biosimilars 52

Biosimilars Pharmacy Production Drugs 52

Science Daily: Pharmacology News

APRIL 3, 2024

The earliest dinosaurs had rapid growth rates, but so did many of the other animals living alongside them, according to a new study.

73

73

Drug Patent Watch

APRIL 3, 2024

EXSERVAN (riluzole) Aquestive Patent: 8,603,514 Expiration: Apr 3, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Science Daily: Pharmacology News

APRIL 3, 2024

One of the most fundamental interactions in physics is that of electrons and light. In an experiment, scientists have now managed to observe what is known as the Kapitza-Dirac effect for the first time in full temporal resolution. This effect was first postulated over 90 years ago, but only now are its finest details coming to light.

Research 52

Research 52

The Premier Consulting Blog

APRIL 3, 2024

Analytical Target Profile The analytical target profile (ATP) concept was first introduced in the ICH Q14 1 Guideline in 2022. This guideline, which compliments the ICH Q2 2 Guideline, describes science and risk-based approaches for developing and maintaining analytical procedures suitable for the evaluation of the quality of drug substances and drug products.

Pharmaceuticals 52

Pharmaceuticals Cell Based Assays Production International 52

Antidote

APRIL 3, 2024

There are many options for clinical trial patient recruitment — digital advertising, in-person campaigns, and doctor’s office flyers are just a few. However, regardless of which avenue a study uses to find eligible individuals, there are a few basic tips that can help create effective outreach.

Clinical Trials 52

Clinical Trials Trials 52

Perficient: Drug Development

APRIL 3, 2024

In the latest episode of “What If, So What?” host Jim Hertzfeld invites Eisaiah Engel, author of “ Innovation Casino ,” to dive deep into the essence of innovation in today’s business landscape. Engel shares his unique perspective on tackling innovation challenges across the spectrum as he and Jim explore the critical role of innovation in achieving differentiated, premium branding and generating alpha returns.

Marketing 52

Marketing Production 52

Drug Patent Watch

APRIL 3, 2024

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Perficient: Drug Development

APRIL 3, 2024

Insurers are constantly striving to improve their operations, provide better experiences for customers, and minimize risks. Perficient insurance experts were interviewed for Forrester’s report, “ The Top Emerging Technologies In Insurance, 2024 ,” and discussed technologies expected to emerge in the insurance industry over the next five years, considering them now, and in the short-term, medium-term, and long-term future.

52

52

Drug Patent Watch

APRIL 3, 2024

Annual Drug Patent Expirations for MINOCIN Minocin is a drug marketed by Bausch, Triax Pharms, Lederle, and Rempex and, and is included in five NDAs.

Drugs 52

Drugs Marketing 52

Alta Sciences

APRIL 3, 2024

Infographic_Thumbnail ehdem Wed, 04/03/2024 - 19:18 Image Infographic_Thumbnail.

40

40

Drug Patent Watch

APRIL 3, 2024

Annual Drug Patent Expirations for BRUKINSA Brukinsa is a drug marketed by Beigene and is included in one NDA. It is available from one supplier.

Drugs 52

Drugs Marketing 52

The Premier Consulting Blog

APRIL 3, 2024

In 2022, ICH Q14 officially introduced the enhanced approach 1 in analytical development as an alternative path to the minimal approach, the benefits of which are worth exploring further. Analytical data is essential in demonstrating the safety and quality of pharmaceutical products and therefore the data should be reliable. A prerequisite for data reliability is a robust and fit-for-purpose analytical method that performs consistently within predefined criteria and per the established performan

Pharmaceuticals 52

Pharmaceuticals Production Compliance International 52

Drug Patent Watch

APRIL 3, 2024

This chart shows the pharmaceutical companies with the most patents in Argentina.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs 52